What happens to a medicine (pralsetinib) when given to people with unhealthy livers
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Pralsetinib in Subjects With Moderate or Severe Hepatic Impairment Compared to Healthy Subjects
Metabolic Disorder Hepatic Insufficiency Liver Failure
For the latest version of this information please go to www.forpatients.roche.com